Adamas Pharmaceuticals, Inc. (ADMS) Swings to Q1 Loss

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) reported Q1 EPS of ($0.67), versus $1.70 reported last year. Revenue for the quarter came in at $176 thousand, versus $30.6 million reported last year.

For earnings history and earnings-related data on Adamas Pharmaceuticals, Inc. (ADMS) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
• Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'